Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19650723 | 1.00 | ATM (0.40) | ATMMAPTEPHX1ACECHRNB2 | |
| SCHEMBL21621509 | 1.00 | ATM (0.40) | ATMMAPTEPHX1ACECHRNB2 | |
| SCHEMBL15077292 | 1.00 | ATM (0.40) | ATMMAPTEPHX1ACECHRNB2 | |
| SCHEMBL15077296 | 1.00 | ATM (0.40) | ATMMAPTEPHX1ACECHRNB2 | |
| SCHEMBL12869332 | 1.00 | ATM (0.40) | ATMMAPTEPHX1ACECHRNB2 | |
| SCHEMBL19090801 | 0.84 | ATM (0.53) | ATMMAPTACEREN | |
| SCHEMBL22853605 | 0.84 | ATM (0.53) | ATMMAPTACEREN | |
| SCHEMBL10105388 | 0.84 | ATM (0.53) | ATMMAPTACEREN | |
| SCHEMBL10021563 | 0.84 | ATM (0.53) | ATMMAPTACEREN | |
| SCHEMBL9108324 | 0.84 | ATM (0.53) | ATMMAPTACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20180201838-A1 | FLAME-RETARDANT POLYOLEFIN SYSTEMS | BASF SE (DE) | 2018-07-19 | — | — | US | disclosed |
| US-20180134832-A1 | QUATERNARY PHOSPHONIUM COATED SURFACES AND METHODS OF MAKING THE SAME | ORTHOBOND INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9884865-B2 | Azaspiro[4.5] decane derivatives and use thereof | PURDUE PHARMA L.P. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9868808-B2 | Quaternary phosphonium coated surfaces and methods of making the same | ORTHOBOND, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2017-10-05 | — | — | US | disclosed |
| US-9763955-B2 | Methods and compositions for decreasing gastric emptying | PURDUE PHARMA L.P. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9718780-B2 | Substituted pyridines as sodium channel blockers | PURDUE PHARMA L.P. | 2017-08-01 | — | — | US | disclosed |
| US-9359330-B2 | Substituted piperidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160145210-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-05-26 | — | — | US | disclosed |
| US-20160115268-A1 | Quaternary Phosphonium Coated Surfaces and Methods of Making the Same | ORTHOBOND, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160024022-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-01-14 | — | — | US | disclosed |
| US-20150336974-A1 | Cyclic Sulfonamides as Sodium Channel Blockers | PURDUE PHARMA L.P. | 2015-11-26 | — | — | US | disclosed |
| US-9133131-B2 | Pyrimidine diol amides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | PURDUE PHARMA L.P. | 2015-06-25 | — | — | US | disclosed |
| US-20150057300-A1 | SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-02-26 | — | — | US | disclosed |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024022-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | ATM 3989/4885MAPT 3818/4885EPHX1 396/4885 |
| US-20170283392-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | ATM 4389/4885MAPT 3286/4885EPHX1 3767/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ATM 234/4885MAPT 3235/4885EPHX1 3226/4885 |
| US-20150175569-A1 | DIBENZAZEPINE DERIVATIVES AND USE THEREOF | CACNA1A, CACNA1D, CACNA1S | ATM 4389/4885MAPT 3286/4885EPHX1 3767/4885 |
| US-20140315783-A1 | PYRIMIDINE DIOL AMIDES AS SODIUM CHANNEL BLOCKERS | TRPV1, P2RX3, CACNA1A | ATM 3735/4885MAPT 3998/4885EPHX1 618/4885 |
| US-20160145210-A1 | SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS | SCN1B, CACNA1A, P2RX1 | ATM 4687/4885MAPT 3220/4885EPHX1 548/4885 |
| US-20160009659-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | CACNA1A, TRPV1, TRPA1 | ATM 4326/4885MAPT 3982/4885EPHX1 1099/4885 |
| US-20150057300-A1 | SUBSTITUTED PIPERIDINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, CACNA1E | ATM 4044/4885MAPT 3185/4885EPHX1 2965/4885 |
| US-20150336974-A1 | Cyclic Sulfonamides as Sodium Channel Blockers | SCN2B, SCN1B, SCN1A | ATM 4007/4885MAPT 4154/4885EPHX1 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.